Skip to main content
Search

# IsoDDE

3 related articles

Subscribe to updates
  1. Venture Capital

    Isomorphic Labs closes a $5 billion Series C to push AI-designed drug candidates toward clinical trials

    Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, continued large investment from Alphabet, and participation from all existing investors. The company says the capital will further mature its in-house drug design engine IsoDDE, expand its internal and partnered candidate pipeline, and build AI-oriented infrastructure for translational and clinical development so candidates can move into clinical trials. The company also reports positive preclinical results in internal oncology and immunology programs and in partnered projects.

  2. Venture Capital

    Isomorphic Labs announces a $5 billion Series C to move its first therapeutic programs toward clinical trials

    Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, continued significant investment from Alphabet, and participation from all existing investors. The company says the capital will fund further development of its proprietary drug-design engine IsoDDE, expansion of its internal and partnered drug-candidate portfolio, and construction of global infrastructure for AI-driven bioengineering and clinical translation. Isomorphic also says its internal oncology and immunology programs and partnered programs have produced positive preclinical results and are paving the way for its first therapeutic programs to enter clinical trials.

  3. Venture Capital

    Isomorphic Labs closes a $5 billion Series C to push its AI-designed drug candidates toward clinical trials

    Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, a continued major investment from Alphabet, and participation from all existing investors. The company says the capital will go toward further developing its proprietary drug-design engine IsoDDE, expanding its internal and partnered candidate portfolio, and building AI infrastructure for translational and clinical development. It also states that internal oncology and immunology programs and partnered projects have produced positive preclinical results, laying the groundwork for entering the clinical stage.

You’re all caught up